Gland Pharma Appoints Xiao Le as CIO of Singapore Subsidiary

Gland Pharma Limited announced the appointment of Mr. Xiao Le as the Chief Investment Officer of its wholly-owned subsidiary, Gland Pharma International Pte. Ltd. (Gland Singapore). This appointment is effective November 09, 2026. Mr. Le will be responsible for identifying and pursuing investment opportunities and enhancing M&A capabilities in key markets including the United States, China, and Singapore. He brings over 15 years of experience in investment and asset management within the medical devices, biopharma, and healthcare services sectors, having previously held positions at prominent organizations like Wuxi AppTec and Bank of America Merrill Lynch. He holds degrees from Johns Hopkins University and MIT.